Participated · Series D · Aug 2026

Abcuro develops immunotherapies intended to benefit people with debilitating and progressive rare autoimmune diseases by selectively targeting and depleting highly cytotoxic T cells. Its lead program, ulviprubart, is a monoclonal antibody that targets killer cell lectin like receptor G1 (KLRG1) and is currently being evaluated for the treatment of Inclusion Body Myositis (IBM). The company plans to use proceeds from the Series D to support a new potentially registrational clinical study of ulviprubart in patients with less severe IBM. Abcuro is led by CEO Alex Martin and is based in Newton, MA. Financially, it has just completed a $66M Series D financing led by New Leaf Venture Partners with participation from a broad syndicate of life sciences and strategic investors.

Participated · Equity · Aug 2026

Slate Medicines is advancing a pipeline of migraine antibody therapeutics designed to go beyond existing CGRP-targeted treatments. Its lead candidate, SLTE-1009 (licensed from DartsBio Pharmaceuticals), is a monoclonal antibody that targets both PACAP and VIP, and the company’s second program, SLTE-2100, is a bispecific antibody combining CGRP and PACAP/VIP blockade. Slate plans to report Phase I safety and PK data for SLTE-1009 in mid-2027 and to start a Phase II migraine study in the second half of 2027. The company positions its dual-targeting approach as potentially offering greater efficacy versus PACAP-only therapies in a market where CGRP-targeted products generated roughly $5 billion in 2025 sales. Slate recently secured a $245 million financing via a reverse merger and private placement and had raised $130 million in a Series A earlier the same year, giving it runway into 2029.

Participated · Series B · Aug 2026

Khartis Therapeutics is developing a pipeline of oral small molecule medicines, with a lead program that is an oral selective IGF-1R inhibitor designed for thyroid eye disease. The company is also advancing additional oral small-molecule programs against clinically validated immunology pathways. Khartis was founded in 2024 by Robert Hoffman (CEO and Head of Drug Discovery), Craig Murphy (CSO), and Chris LeMasters (Executive Chairman), and was incubated within Foresite Labs. It is headquartered in San Diego and its team includes many members who previously worked together at XinThera. Financially, Khartis has raised a total of $95 million following its $50 million Series B. The company intends to use the new financing to accelerate advancement of its lead program and continue discovery of differentiated small molecule medicines.

Participated · Series C · Jun 2026

Stepful offers a vertically integrated, AI-enabled training platform that delivers school-as-a-service to health systems, covering instruction, simulation, assessment, and workforce planning. The platform provides employer-sponsored, debt-free pathways enabling learners to move from a high school diploma to healthcare careers while remaining in the workforce and avoiding traditional trade-school debt. Stepful connects graduates directly to job opportunities after certification and reports graduating more than 32,000 practice-ready healthcare workers. The company serves 35+ major healthcare system clients, including Mount Sinai, Ochsner, and Providence, and has seen meaningful revenue growth. Stepful plans to expand partnerships with hospitals and health systems and to launch advanced degree programs in nursing, respiratory therapy, and imaging while accelerating its AI capabilities. The company was founded by Carl Madi, Tressia Hobeika, and Edoardo Serra.

Led · Series B · Mar 2026

Pinnacle Medicines is developing a generation of oral peptide medicines designed to deliver biologic-level efficacy with oral dosing. The company combines physics-based molecular simulations, artificial intelligence–enabled design, and advanced peptide chemistry in a proprietary discovery platform. Pinnacle is advancing a pipeline of potential first- and best-in-class oral peptide programs targeting validated pathways in immunology and cardiometabolic diseases. The recent $89 million Series B will support progressing lead programs toward clinical proof of concept and expanding R&D capabilities. Pinnacle has raised $134 million to date following incubation by OrbiMed and other healthcare specialist investors. The company operates out of Shanghai and Doylestown, Pennsylvania.